Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Verstovsek on Benefit of Ruxolitinib in Polycythemia Vera

January 31st 2019

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the benefit of ruxolitinib in polycythemia vera.

Dr. Shah on Investigational Agents in CML

January 30th 2019

Neil Shah, MD, PhD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco (UCSF) Program Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses investigational agents in chronic myeloid leukemia (CML).

Dr. Kaplan on the Phase III ECHELON-1 Trial in Hodgkin Lymphoma

January 29th 2019

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the results of the phase III ECHELON-1 trial in Hodgkin lymphoma.

The Current Unmet Needs in PTCL Treatment and Prospects

January 28th 2019

PTCL Treatment in the Community Setting

January 28th 2019

The Impact of Brentuximab Vedotin as PTCL Treatment

January 28th 2019

Treating Patients With CD30-Positive PTCL

January 28th 2019

An Overview of Peripheral T-Cell Lymphoma

January 28th 2019

PTCL Community Treatment and Future Advancements

January 28th 2019

The ECHELON-2 Trial Presented at ASH 2018

January 28th 2019

Brentuximab Vedotin Overview and Treatment Advice

January 28th 2019

T-Cell Lymphoma Differential Diagnosis and CD30 Treatment

January 28th 2019

Peripheral T-Cell Lymphoma Classifications and CD30 Testing

January 28th 2019

Dr. Oh Discusses the Differences Between Investigational JAK Inhibitors and Ruxolitinib in MPNs

January 26th 2019

Stephen Oh, MD, PhD, assistant professor of medicine, Division of Hematology, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the differences between investigational JAK inhibitors and ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms (MPNs).

Blood Cancers Associated With Higher Treatment and Out-of-Pocket Costs

January 25th 2019

Patients with blood cancers face greater treatment costs than those with solid tumors. Furthermore, healthcare spending for these patients is already higher than average before diagnosis and does not return to prediagnosis levels even after successful treatment.

The Future of ITP Treatment

January 24th 2019

Rituximab and Salvage Therapies for Patients With ITP

January 24th 2019

TPO Duration of Response and Toxicity

January 24th 2019

TPO Receptor Agonist Selection and Patient Adherence

January 24th 2019

Romiplostim Classification and Mechanism of Action

January 24th 2019